Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease

被引：109

作者：

Ho P.M. ^{[1
,2
]}

Magid D.J. ^{[3
,4
]}

Masoudi F.A. ^{[2
,5
]}

McClure D.L. ^{[4
]}

Rumsfeld J.S. ^{[1
,2
]}

机构：

[1] Cardiology Section, Denver VA Medical Center, Denver, CO

[2] Department of Medicine, University of Colorado Health Sciences Center, Denver, CO

[3] Department of Biometrics and Preventive Medicine, University of Colorado Health Sciences Center, Denver, CO

[4] Clinical Research Unit, Kaiser Permanente of Colorado, Denver, CO

[5] Department of Medicine, Denver Health Medical Center, Denver, CO

来源：

BMC Cardiovascular Disorders | / 6卷 / 1期

关键词：

Ischemic Heart Disease; Medication Adherence; Adherent Patient; Statin Medication; Chronic Ischemic Heart Disease;

D O I：

10.1186/1471-2261-6-48

中图分类号：

学科分类号：

摘要：

Background: Patients with diabetes and ischemic heart disease (IHD) are at high risk for adverse cardiac outcomes. Clinical practice guidelines recommend multiple cardioprotective medications to reduce recurrent events. We evaluated the association between cardioprotective medication adherence and mortality among patients with diabetes and IHD. Methods: In a retrospective cohort study of 3,998 patients with diabetes and IHD, we evaluated use of ACE inhibitors or angiotensin receptor blockers, β-blockers, and statin medications. Receipt of cardioprotective medications was based on filled prescriptions. Medication adherence was calculated as the proportion of days covered (PDC) for filled prescriptions. The primary outcome of interest was all-cause mortality. Results: The majority of patients (92.8%) received at least 1 cardioprotective medication. Patients receiving any medications had lower unadjusted mortality rates compared to patients not receiving any medications (7.9% vs. 11.5%; p = 0.03). In multivariable analysis, receipt of any cardioprotective medication remained associated with lower all-cause mortality (OR 0.65; 95% CI 0.43-0.99). Among patients receiving cardioprotective medications, the majority (80.3%) were adherent (PDC ≥ 0.80). Adherent patients had lower unadjusted mortality rates (6.7% vs. 12.1%; p < 0.01). In multivariable analysis, medication adherence remained associated with lower all-cause mortality (OR 0.52; 95% CI 0.39-0.69) compared to non-adherence. In contrast, there was no mortality difference between patients receiving cardioprotective medications who were non-adherent compared to patients not receiving any medications (OR 1.01; 95% CI 0.64-1.61). Conclusion: In conclusion, medication adherence is associated with improved outcomes among patients with diabetes and IHD. Quality improvement interventions are needed to increase medication adherence in order for patients to maximize the benefit of cardioprotective medications. © 2006 Ho et al; licensee BioMed Central Ltd.

引用

共 31 条

[21] Brown L.C., Johnson J.A., Majumdar S.R., Tsuyuki R.T., McAlister F.A., Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis, CMAJ, 171, 10, pp. 1189-11892, (2004)
[22] Blackburn D.F., Dobson R.T., Blackburn J.L., Wilson T.W., Stang M.R., Semchuk W.M., Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study, Can J Cardiol, 21, 6, pp. 485-488, (2005)
[23] Heisler M., Smith D.M., Hayward R.A., Krein S.L., Kerr E.A., How well do patients' assessments of their diabetes self-management correlate with actual glycemic control and receipt of recommended diabetes services?, Diabetes Care, 26, 3, pp. 738-743, (2003)
[24] O'donovan G., Owen A., Kearney E.M., Jones D.W., Nevill A.M., Woolf-May K., Bird S.R., Cardiovascular disease risk factors in habitual exercisers, lean sedentary men and abdominally obese sedentary men, Int J Obes Relat Metab Disord, (2005)
[25] Hu G., Jousilahti P., Barengo N.C., Qiao Q., Lakka T.A., Tuomilehto J., Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes, Diabetes Care, 28, 4, pp. 799-805, (2005)
[26] Horwitz R., Viscoli C.M., Berkman L., Donaldson R.M., Horwitz R.M., Murray C.J., Ransohoff D.F., Sindelar J., Treatment adherence and risk of death after a myocardial infarction, Lancet, 336, pp. 542-545, (1990)
[27] Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project Group, N Engl J Med, 303, pp. 1038-1041, (1980)
[28] Irvine J., Baker B., Smith J., Jandciu S., Paquette M., Cairns J., Connolly S., Roberts R., Gent M., Dorian P., Poor adherence to placebo or amiodarone therapy predicts mortality: Results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial, Psychosom Med, 61, 4, pp. 566-575, (1999)
[29] Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., Mullany C.J., Ornato J.P., Pearle D.L., Sloan M.A., Smith Jr. S.C., Alpert J.S., Anderson J.L., Faxon D.P., Fuster V., Gibbons R.J., Gregoratos G., Halperin J.L., Hiratzka L.F., Hunt S.A., Jacobs A.K., Ornato J.P., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction
[30] A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction), J Am Coll Cardiol, 44, 3, (2004)

← 1 2 3 4 →